Fas and Fas ligand expressed on cells of the immune system, not on the target tissue, control induction of experimental autoimmune uveitis.
The Fas-Fas ligand (FasL) interaction is important for maintaining lymphocyte homeostasis by signaling for activation-induced cell death. Mice homozygous for the lpr or gld mutations do not express functional Fas or FasL, respectively, and spontaneously develop progressive autoimmune symptoms. Recent studies implicated expression of FasL on immunologically privileged tissues in protection from immune-mediated damage. Conversely, tissue expression of Fas may facilitate damage. We evaluated the susceptibility of lpr and gld mice to induction of experimental autoimmune uveitis (EAU), a T cell-mediated autoimmune disease induced with retinal Ags, which targets the neural retina. gld as well as lpr mice immunized with a retinal Ag developed disease of lower incidence and severity than wild-type controls. Delayed hypersensitivity responses were not significantly different among immunized gld, lpr, or wild-type mice, although in vitro Ag-specific lymphocyte responses of the mutant mice were lower. To evaluate whether the diminished ability of gld and lpr mice to develop EAU was due to a defect at the level of the tissue or the immune system, radiation bone marrow chimeras constructed between wild-type and mutant mice were immunized to induce EAU. Mutant recipients of wild-type bone marrow, but not wild-type recipients of mutant bone marrow, developed normal disease scores. These results indicate that normal expression of Fas and of FasL on cells of the immune system is important for EAU expression. Unexpectedly, neither lack of Fas nor lack of FasL on the ocular tissues affected expression of EAU.
Wahlsten
J L
JL
Laboratory of Immunology, National Eye Institute, National Institutes of Health, Bethesda, MD 20892, USA.
Gitchell
H L
HL
Chan
C C
CC
Wiggert
B
B
Caspi
R R
RR
D000818:Animals; D001327:Autoimmune Diseases / Q000209:etiology* / Q000235:genetics / Q000473:pathology; D016026:Bone Marrow Transplantation / Q000276:immunology; D002417:Cattle; D004198:Disease Susceptibility / Q000276:immunology; D015536:Down-Regulation / Q000235:genetics / Q000276:immunology; D005136:Eye Proteins / Q000008:administration & dosage / Q000276:immunology; D053222:Fas Ligand Protein; D020022:Genetic Predisposition to Disease; D007107:Immune System / Q000166:cytology* / Q000276:immunology / Q000378:metabolism*; D007279:Injections, Subcutaneous; D008024:Ligands; D008562:Membrane Glycoproteins / Q000096:biosynthesis*; D051379:Mice; D020297:Mice, Congenic; D008810:Mice, Inbred C57BL; D019463:Mice, Inbred MRL lpr; D008817:Mice, Mutant Strains; D009928:Organ Specificity / Q000235:genetics / Q000276:immunology; D011828:Radiation Chimera / Q000276:immunology; D012173:Retinitis / Q000235:genetics / Q000276:immunology / Q000473:pathology; D012177:Retinol-Binding Proteins / Q000008:administration & dosage / Q000276:immunology; D014605:Uveitis / Q000235:genetics / Q000276:immunology* / Q000473:pathology; D019014:fas Receptor / Q000096:biosynthesis* / Q000378:metabolism; D000099214:Retinol-Binding Proteins, Interstitial
D005136:Eye Proteins; D053222:Fas Ligand Protein; D008024:Ligands; D008562:Membrane Glycoproteins; D012177:Retinol-Binding Proteins; D019014:fas Receptor; D000099214:Retinol-Binding Proteins, Interstitial; C505658:Fasl protein, mouse